Congress passed H.R. 8205, the Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
The Senate approved the legislation on September 28, and the Government Publishing Office has the enrolled text. As of this article’s October 28 preparation, RAA has not verified presidential signature. This article explains the enrolled bill’s provisions without treating them as enacted requirements.
What the existing program does
The original ACT for ALS established federal programs supporting research and access to investigational treatments.
NIH’s expanded-access grants support both access to investigational drugs for people with ALS and research using information collected through those programs. These arrangements can serve people who cannot enroll in a clinical trial.
A Government Accountability Office review explains that expanded access operates through an FDA pathway for serious or life-threatening conditions when clinical-trial enrollment is not possible.
What H.R.8205 would change
The enrolled legislation would extend the act’s authorization and the ALS research-grant authorization through fiscal year 2031.
It would also:
Require grant-renewal reviews to assess enrollment, safety, and available efficacy data from the manufacturer or sponsor.
Add prompt reporting to the grant-making institution of specified serious adverse events and unexpected safety information, alongside existing safety-reporting obligations.
Clarify that the relevant “phase 3” definition includes certain combined phase 2/3 trials, subject to grant conditions.
Require an FDA rare-neurodegenerative-disease action plan within 18 months of enactment, covering the following five years.
Require a report on FDA’s actions within five years of enactment.
Those deadlines would run from enactment, rather than from congressional passage.
Expanded access is different from drug approval
Expanded access can provide a potential treatment pathway outside clinical trials when satisfactory alternatives are unavailable.
It does not establish that an investigational product is safe and effective for a particular use. The FDA’s patient information makes clear that these products have not yet received the relevant approval or clearance.
Families should therefore distinguish between legislation supporting access, an individual program’s eligibility requirements, and evidence about a treatment.
Why communities and organizations should pay attention
For research institutions, patient-support nonprofits, and healthcare organizations, the legislation concerns the continuity and oversight of programs serving people affected by ALS.
For families, it is useful background for conversations with care teams about research and expanded-access opportunities. Passing a reauthorization bill does not enroll a patient or guarantee access to treatment.
Organizations sharing the news should identify the legislative status and direct readers to the relevant agency or participating institution for current program information.
Sources: H.R.8205 enrolled text; GAO review of rare-disease research and ALS investigational-drug access; FDA expanded-access information.